公开(公告)号：US20200268799A1

公开(公告)日：2020-08-27

申请号：US16871156

申请日：2020-05-11

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61P35/00 ,  A61K39/39 ,  C07K16/28 ,  C07K7/06 ,  C07K14/54 ,  A61P35/02 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/12 ,  C07K16/24 ,  A61K39/395 ,  A61K38/08 ,  C07K14/47

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200261505A1

公开(公告)日：2020-08-20

申请号：US16833146

申请日：2020-03-27

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  C07K16/28 ,  A61K39/395 ,  C07K16/24 ,  A61K39/12 ,  A61K39/00 ,  C12N5/0783 ,  A61K45/06 ,  A61P35/02 ,  C07K14/47 ,  A61K38/08 ,  C07K14/54 ,  C07K7/06 ,  A61K39/39 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200261504A1

公开(公告)日：2020-08-20

申请号：US16833110

申请日：2020-03-27

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  C07K16/28 ,  A61K39/395 ,  C07K16/24 ,  A61K39/12 ,  A61K39/00 ,  C12N5/0783 ,  A61K45/06 ,  A61P35/02 ,  C07K14/47 ,  A61K38/08 ,  C07K14/54 ,  C07K7/06 ,  A61K39/39 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200108097A1

公开(公告)日：2020-04-09

申请号：US16703061

申请日：2019-12-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  C07K16/24 ,  A61K39/00 ,  C07K14/47 ,  C07K16/28 ,  A61K39/12 ,  C07K14/54 ,  C07K7/06 ,  A61P35/02 ,  A61P35/00 ,  A61K45/06 ,  C12N5/0783 ,  A61K39/395 ,  A61K39/39 ,  A61K38/08

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200093862A1

公开(公告)日：2020-03-26

申请号：US16703034

申请日：2019-12-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  A61K39/00 ,  C07K16/28 ,  C07K14/47 ,  C07K14/54 ,  C07K7/06 ,  A61P35/02 ,  A61K39/12 ,  A61K38/08 ,  C07K16/24 ,  A61K39/39 ,  A61K39/395 ,  C12N5/0783 ,  A61K45/06 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20200085874A1

公开(公告)日：2020-03-19

申请号：US16692108

申请日：2019-11-22

Applicant: Immatics Biotechnologies GmbH

Inventor： Heiko SCHUSTER ,  Franziska HOFFGAARD ,  Jens FRITSCHE ,  Oliver SCHOOR ,  Toni WEINSCHENK ,  Daniel Johannes KOWALEWSKI ,  Chih-Chiang TSOU

IPC: A61K35/17 ,  C07K16/24 ,  A61K39/12 ,  C07K14/47 ,  A61K39/00 ,  C07K14/54 ,  C07K7/06 ,  A61P35/02 ,  A61K38/08 ,  C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K39/39 ,  C12N5/0783 ,  A61P35/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20240374640A1

公开(公告)日：2024-11-14

申请号：US18599838

申请日：2024-03-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240358756A1

公开(公告)日：2024-10-31

申请号：US18599924

申请日：2024-03-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4748 ,  C12N5/0636

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240299455A1

公开(公告)日：2024-09-12

申请号：US18599860

申请日：2024-03-08

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4748 ,  C12N5/0636

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20240269184A1

公开(公告)日：2024-08-15

申请号：US18606764

申请日：2024-03-15

Applicant: Immatics Biotechnologies GmbH

Inventor： Ricarda HANNEN ,  Jens HUKELMANN ,  Florian KOEHLER ,  Daniel Johannes KOWALEWSKI ,  Heiko SCHUSTER ,  Oliver SCHOOR ,  Michael ROEMER ,  Chih-Chiang TSOU ,  Jens FRITSCHE

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K39/0011 ,  A61P35/00 ,  C07K14/4748 ,  C12N5/0636

Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.